Last reviewed · How we verify
Exendin 9-39
Exendin 9-39 is a Small molecule drug developed by University of Chicago. It is currently FDA-approved. Also known as: Glucagon-Like Peptide 1 (GLP-1) receptor antagonist, Ex(9-39), GLP-1 antagonist, GLP-1 receptor antagonist.
Exendin 9-39 is a GLP-1R antagonist used in clinical trials to study its effects on various conditions, including Postural Orthostatic Tachycardia Syndrome (POTS) and glucose metabolism disorders. It has also been tested in trials involving healthy subjects to examine its impact on gastric emptying and other physiological processes.
At a glance
| Generic name | Exendin 9-39 |
|---|---|
| Also known as | Glucagon-Like Peptide 1 (GLP-1) receptor antagonist, Ex(9-39), GLP-1 antagonist, GLP-1 receptor antagonist, Avexitide |
| Sponsor | University of Chicago |
| Modality | Small molecule |
| Phase | FDA-approved |
Approved indications
Common side effects
Key clinical trials
- Avexitide for Treatment of Post-Bariatric Hypoglycemia (PHASE3)
- The Effect of rs7903146 Genotype on Islet GLP-1 Production in Humans (PHASE2)
- The Effect of Endogenous GLP-1 on Glucagon Secretion in Type 1 Diabetes (NA)
- The Role of Islet GLP-1 in the Pathogenesis of Prediabetes (PHASE2)
- The Effects of Glucagon on Renal Regional Blood Flow in Humans Measured by Magnetic Resonance. (NA)
- Glucagon-like Peptide 1, Glucose Metabolism and Gastric Bypass (EARLY_PHASE1)
- Role of Neural and Hormonal Regulation Factors on Insulin Secretion After Gastric Bypass Surgery (EARLY_PHASE1)
- The Effects of Bariatric Surgeries on Glucose Metabolism (EARLY_PHASE1)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Exendin 9-39 CI brief — competitive landscape report
- Exendin 9-39 updates RSS · CI watch RSS
- University of Chicago portfolio CI
Frequently asked questions about Exendin 9-39
What is Exendin 9-39?
Who makes Exendin 9-39?
Is Exendin 9-39 also known as anything else?
What development phase is Exendin 9-39 in?
Related
- Manufacturer: University of Chicago — full pipeline
- Also known as: Glucagon-Like Peptide 1 (GLP-1) receptor antagonist, Ex(9-39), GLP-1 antagonist, GLP-1 receptor antagonist, Avexitide
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing